Maintaining a robust patent estate is a critical task for many corporations, particularly those operating in innovative fields. In the biotech industry, this task becomes particularly paramount due to the highly competitive nature of the environment and the significant investments often required for research and development.
Emerging biotech companies often face a myriad of challenges when it comes to patent protection. This issue was recently discussed by Stephen Altieri, a partner at the law firm Morgan Lewis. Altieri, who is part of a comprehensive cross-practice life sciences team comprising 250 members, highlighted the necessity of efficient patent protection during the Biotech Week Boston event. The conversation also involved patent agent Emily Coury, who offered her insights on the matter.
One of the key points highlighted during this discussion is that an effective patent protection strategy is one that makes a company attractive to potential investors and partners. These entities typically look for patent estates that are “partner-ready,” indicating that the patents in question have been thoroughly examined, defensible against legal challenges, and offers a clear competitive advantage in the market.
This dialogue sheds light on the need for precise and strategic patent protection planning, especially in an industry as competitive as biotech. A meticulously built and maintained patent estate can not only protect a corporation’s intellectual property but also significantly enhance its value and attractiveness to potential partners and investors.
For more detailed insights from Stephen Altieri and Emily Coury, see their discussion on biotech patent protection on JD Supra.